Menu

Flu Drug Approved in Japan Claims to Stop Virus in 24 Hours

One dose of the medication, called Xofluza, cripples influenza by interfering with an enzyme critical for viral replication.  

Feb 26, 2018
Kerry Grens

FLICKR, SANOFI PASTEURHealth authorities in Japan on Friday (February 23) approved a new flu medication, called baloxavir marboxil (Xofluza), that aims to stop the virus within one day, according to The Wall Street Journal.

The drug works by blocking the flu virus’s ability to use the host cell for replication. That’s a different mechanism from oseltamivir (Tamiflu), an anti-influenza medication available in the U.S. that works by blocking the virus’s neuraminidase enzyme, preventing its escape from the host cell.

“The data that we’ve seen looks very promising,” Martin Howell Friede, head of the World Health Organization’s advisory on vaccines, told the Journal earlier in the month. “This could be a breakthrough in the way that we treat influenza.”

Data from the drugmaker, Shionogi, show that while Xofluza works days faster than Tamiflu in stopping the flu virus, symptoms wrap up in about the same timeframe for either medication. Roche, which makes Tamiflu, has acquired the license to sell Xofluza internationally, but it will be another year until it could be available in the U.S., according to the Journal.

According to Nikkei Asian Review, Xofluza is the first drug Japan has approved via its fast-track system and will be available to patients there once the pricing is set.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.